Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis

Guide for the Care and Use of Laboratory Animals: Eighth Edition

(2011) · doi:10.17226/12910 · Cited by 16,199 · see citing works

Guide for the Care and Use of Laboratory Animals (8th edn)

Albus, U. (2012) · Laboratory Animals · doi:10.1258/la.2012.150312 · Cited by 1,706 · see citing works

Epidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients

Marr, K. A., Carter, R. A., Crippa, F., Wald, A., & Corey, L. (2002) · Clinical Infectious Diseases · doi:10.1086/339202 · Cited by 1,446 · see citing works

Fusarium Infections in Immunocompromised Patients

Nucci, M., & Anaissie, E. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00014-07 · Cited by 979 · see citing works

Infections Caused by <i>Scedosporium</i> spp

Cortez, K. J., Roilides, E., Quiroz-Telles, F., Meletiadis, J., Antachopoulos, C., Knudsen, T., Buchanan, W., Milanovich, J., Sutton, D. A., Fothergill, A., et al. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00039-07 · Cited by 786 · see citing works

Reference method for broth dilution antifungal susceptibility testing of filamentous fungi : Approved standard

Rex, J. H., & Clinical (2008) · Clinical and Laboratory Standards Institute eBooks · Cited by 695 · see citing works

ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others

Tortorano, A. M., Richardson, M. D., Roilides, E., van Diepeningen, A., Caira, M., Munoz, P., Johnson, E. M., Meletiadis, J., Pana, Z. D., Lackner, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12465 · Cited by 517 · see citing works

Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection

Nucci, M., Anaissie, E. J., Queiroz‐Telles, F., Martins, C. A. S., Trabasso, P., Solza, C., Mangini, C., Simões, B. P., Colombo, A. L., Vaz, J., et al. (2003) · Cancer · doi:10.1002/cncr.11510 · Cited by 313 · see citing works

Quantitative PCR Assay To Measure Aspergillus fumigatus Burden in a Murine Model of Disseminated Aspergillosis: Demonstration of Efficacy of Caspofungin Acetate

Bowman, J. C., Abruzzo, G. K., Anderson, J. W., Flattery, A. M., Gill, C. J., Pikounis, V. B., Schmatz, D. M., Liberator, P., & Douglas, C. M. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3474-3481.2001 · Cited by 208 · see citing works

E1210, a New Broad-Spectrum Antifungal, Suppresses Candida albicans Hyphal Growth through Inhibition of Glycosylphosphatidylinositol Biosynthesis

Watanabe, N.-A., Miyazaki, M., Horii, T., Sagane, K., Tsukahara, K., & Hata, K. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00731-11 · Cited by 169 · see citing works

Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis

Hata, K., Horii, T., Miyazaki, M., Watanabe, N.-A., Okubo, M., Sonoda, J., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00366-11 · Cited by 149 · see citing works

<i>In Vitro</i> and <i>In Vivo</i> Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris

Hager, C. L., Larkin, E. L., Long, L., Zohra Abidi, F., Shaw, K. J., & Ghannoum, M. A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02319-17 · Cited by 139 · see citing works

Novel Inhalational Murine Model of Invasive Pulmonary Aspergillosis

Sheppard, D. C., Rieg, G. K., Chiang, L. Y., Filler, S. G., Edwards, J. E., & Ibrahim, A. S. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1908-1911.2004 · Cited by 133 · see citing works

GWT1 Gene Is Required for Inositol Acylation of Glycosylphosphatidylinositol Anchors in Yeast

Umemura, M., Okamoto, M., Nakayama, K.-I., Sagane, K., Tsukahara, K., Hata, K., & Jigami, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301044200 · Cited by 127 · see citing works

Current antifungal treatment of fusariosis

Al‐Hatmi, A. M. S., Bonifáz, A., Ranque, S., de Hoog, S., Verweij, P. E., & Meis, J. F. G. M. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.06.017 · Cited by 123 · see citing works

<i>In Vitro</i> and <i>In Vivo</i> Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus

Shaw, K. J., Schell, W. A., Covel, J., Duboc, G., Giamberardino, C., Kapoor, M., Moloney, M., Soltow, Q. A., Tenor, J. L., Toffaletti, D. L., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00523-18 · Cited by 121 · see citing works

Effective Dosing Regimen of 1-Aminobenzotriazole for Inhibition of Antipyrine Clearance in Rats, Dogs, and Monkeys

Balani, S. K., Zhu, T., Yang, T. J., Liu, Z., He, B., & Lee, F. W. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.10.1059 · Cited by 112 · see citing works

Activities of E1210 and Comparator Agents Tested by CLSI and EUCAST Broth Microdilution Methods against Fusarium and Scedosporium Species Identified Using Molecular Methods

Castanheira, M., Duncanson, F. P., Diekema, D. J., Guarro, J., Jones, R. N., & Pfaller, M. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05414-11 · Cited by 98 · see citing works

<i>In Vitro</i> Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected during an International Surveillance Program in 2017

Pfaller, M. A., Huband, M. D., Flamm, R. K., Bien, P. A., & Castanheira, M. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00840-19 · Cited by 80 · see citing works

Pharmacodynamics of the Orotomides against Aspergillus fumigatus : New Opportunities for Treatment of Multidrug-Resistant Fungal Disease

Hope, W. W., McEntee, L., Livermore, J., Whalley, S., Johnson, A., Farrington, N., Kolamunnage‐Dona, R., Schwartz, J., Kennedy, A. J., Law, D., et al. (2017) · mBio · doi:10.1128/mbio.01157-17 · Cited by 78 · see citing works

Efficacy of Liposomal Amphotericin B and Posaconazole in Intratracheal Models of Murine Mucormycosis

Luo, G., Gebremariam, T., Lee, H.-K., French, S. W., Wiederhold, N. P., Patterson, T. F., Filler, S. G., & Ibrahim, A. S. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00313-13 · Cited by 73 · see citing works

Invasive fungal infections in acute leukemia

Bhatt, V. R., Viola, G. M., & Ferrajoli, A. (2011) · Therapeutic Advances in Hematology · doi:10.1177/2040620711410098 · Cited by 71 · see citing works

<i>In Vivo</i> Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model

Zhao, M., Lepak, A. J., VanScoy, B., Bader, J. C., Marchillo, K., Vanhecker, J., Ambrose, P. G., & Andes, D. R. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02542-17 · Cited by 68 · see citing works

Improving the mouse model for studying the efficacy of voriconazole

Graybill, J. R. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg261 · Cited by 58 · see citing works

APX001 Pharmacokinetic/Pharmacodynamic Target Determination against Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis

Zhao, M., Lepak, A. J., Marchillo, K., VanHecker, J., Sánchez, H., Ambrose, P. G., & Andes, D. R. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02372-18 · Cited by 51 · see citing works

Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001 and to Investigate the Effect of Food on APX001 Bioavailability

Hodges, M. R., Ople, E., Shaw, K. J., Mansbach, R. S., van Marle, S. P., van Hoogdalem, E., Kramer, W. G., & Wedel, P. C. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx163.1390 · Cited by 45 · see citing works

APX001 Is Effective in the Treatment of Murine Invasive Pulmonary Aspergillosis

Gebremariam, T., Alkhazraji, S., Alqarihi, A., Jeon, H. H., Gu, Y., Kapoor, M., Shaw, K. J., & Ibrahim, A. S. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01713-18 · Cited by 44 · see citing works

Significantly Improved Pharmacokinetics Enhances In Vivo Efficacy of APX001 against Echinocandin- and Multidrug-Resistant Candida Isolates in a Mouse Model of Invasive Candidiasis

Zhao, Y., Lee, M. H., Paderu, P., Lee, A., Jiménez‐Ortigosa, C., Park, S., Mansbach, R. S., Shaw, K. J., & Perlin, D. S. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00425-18 · Cited by 42 · see citing works

First-in-Human Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects

Hodges, M. R., Ople, E., Shaw, K. J., Mansbach, R. S., van Marle, S., van Hoogdalem, E., Wedel, P. C., & Kramer, W. G. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx163.1370 · Cited by 40 · see citing works

Efficacy of Posaconazole as Treatment and Prophylaxis against Fusarium solani

Wiederhold, N. P., Najvar, L. K., Bocanegra, R. A., Graybill, J. R., & Patterson, T. F. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01445-09 · Cited by 27 · see citing works

Comparison of antifungal treatments for murine fusariosis

Spellberg, B. J., Schwartz, J., Fu, Y., Avanesian, V., Adler‐Moore, J., Edwards, J. E., & Ibrahim, A. S. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl378 · Cited by 25 · see citing works

Approaches to management of fungal infections in cancer patients.

Francis, P., & Tj, W. (1992) · PubMed · Cited by 21 · see citing works

2393. Evaluation of Antifungal Treatment in a Neutropenic Mouse Model of Scedosporiosis

Alkhazraji, S., Gebremariam, T., Alqarihi, A., Baldin, C., Wiederhold, N. P., Kitt, T. M., & Ibrahim, A. S. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy210.2046 · Cited by 1 · see citing works

The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin

Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs · doi:10.1007/s40265-021-01611-0 · Cited by 467 · see citing works

Antifungal Drugs

Houšť, J., Spížek, J., & Havlı́ček, V. (2020) · Metabolites · doi:10.3390/metabo10030106 · Cited by 258 · see citing works

Aspiring Antifungals: Review of Current Antifungal Pipeline Developments

Gintjee, T., Donnelley, M., & Thompson, G. (2020) · Journal of Fungi · doi:10.3390/jof6010028 · Cited by 225 · see citing works

Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections

Shaw, K. J., & Ibrahim, A. S. (2020) · Journal of Fungi · doi:10.3390/jof6040239 · Cited by 229 · see citing works

Antifungals: From Pharmacokinetics to Clinical Practice

do Carmo, A., Rocha, M. J., Pereirinha, P., Tomé, R., & Costa, E. (2023) · Antibiotics · doi:10.3390/antibiotics12050884 · Cited by 112 · see citing works

Candidiasis: From cutaneous to systemic, new perspectives of potential targets and therapeutic strategies

Lu, H., Hong, T., Jiang, Y., Whiteway, M. S., & Zhang, S. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114960 · Cited by 96 · see citing works

Fosmanogepix (APX001) Is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to Rhizopus arrhizus

Gebremariam, T., Alkhazraji, S., Alqarihi, A., Wiederhold, N. P., Shaw, K. J., Patterson, T. F., Filler, S. G., & Ibrahim, A. S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00178-20 · Cited by 88 · see citing works

Antifungal Resistance and the Role of New Therapeutic Agents

Logan, A., Wolfe, A. L., & Williamson, J. (2022) · Current Infectious Disease Reports · doi:10.1007/s11908-022-00782-5 · Cited by 87 · see citing works

Development and research progress of anti-drug resistant fungal drugs

Cui, X., Wang, L., Lü, Y., & Yue, C. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.08.004 · Cited by 85 · see citing works

Investigational Antifungal Agents for Invasive Mycoses: A Clinical Perspective

Lamoth, F., Lewis, R. E., & Kontoyiannis, D. P. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1070 · Cited by 79 · see citing works

Novel antifungal agents in clinical trials

Jacobs, S. E., Zagaliotis, P., & Walsh, T. J. (2021) · F1000Research · doi:10.12688/f1000research.28327.1 · Cited by 75 · see citing works

<i>In Vivo</i> Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model

Zhao, M., Lepak, A. J., VanScoy, B., Bader, J. C., Marchillo, K., Vanhecker, J., Ambrose, P. G., & Andes, D. R. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02542-17 · Cited by 68 · see citing works

Consensus guidelines for the diagnosis and management of invasive fungal disease due to moulds other than Aspergillus in the haematology/oncology setting, 2021

Bupha‐Intr, O., Butters, C. T., Reynolds, G. K., Kennedy, K., Meyer, W., Patil, S. S., Bryant, P. A., & Morrissey, C. O. (2021) · Internal Medicine Journal · doi:10.1111/imj.15592 · Cited by 71 · see citing works

Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents

Wiederhold, N. P. (2022) · Journal of Fungi · doi:10.3390/jof8080857 · Cited by 68 · see citing works

The Combination Treatment of Fosmanogepix and Liposomal Amphotericin B Is Superior to Monotherapy in Treating Experimental Invasive Mold Infections

Gebremariam, T., Gu, Y., Alkhazraji, S., Youssef, E. G., Shaw, K. J., & Ibrahim, A. S. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00380-22 · Cited by 61 · see citing works

COVID-19-associated candidiasis and the emerging concern of Candida auris infections

Tsai, C.-S., Lee, S. S., Chen, W.-C., Tseng, C.-H., Lee, N., Chen, P., Li, M.-C., Syue, L.-S., Lo, C.-L., Ko, W., et al. (2022) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2022.12.002 · Cited by 58 · see citing works

Potential Strategies to Control the Risk of Antifungal Resistance in Humans: A Comprehensive Review

Rabaan, A. A., Sulaiman, T., Al-Ahmed, S. H., Buhaliqah, Z. A., Buhaliqah, A. A., AlYuosof, B., Alfaresi, M. S., Fares, M. A. A., Alwarthan, S. M., Alkathlan, M. S., et al. (2023) · Antibiotics · doi:10.3390/antibiotics12030608 · Cited by 53 · see citing works

Scedosporiosis and lomentosporiosis: modern perspectives on these difficult-to-treat rare mold infections

Neoh, C. F., Chen, S. C. ‐., Lanternier, F., Tio, S. Y., Halliday, C. L., Kidd, S. E., Kong, D. C. M., Meyer, W., Hoenigl, M., & Slavin, M. A. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00004-23 · Cited by 53 · see citing works

Antifungal Pipeline

McCarty, T. P., & Pappas, P. G. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.732223 · Cited by 47 · see citing works

Fungal lung disease

Jaggi, T. K., Agarwal, R., Tiew, P. Y., Shah, A., Lydon, E., Hage, C. A., WATERER, G. W., Langelier, C., Delhaès, L., & Chotirmall, S. H. (2024) · European Respiratory Journal · doi:10.1183/13993003.00803-2024 · Cited by 50 · see citing works

Efficacy and Pharmacokinetics of Fosmanogepix (APX001) in the Treatment of Candida Endophthalmitis and Hematogenous Meningoencephalitis in Nonneutropenic Rabbits

Petraitienė, R., Petraitis, V., Maung, B. B. W., Mansbach, R. S., Hodges, M. R., Finkelman, M., Shaw, K. J., & Walsh, T. J. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01795-20 · Cited by 43 · see citing works

Manogepix, the Active Moiety of the Investigational Agent Fosmanogepix, Demonstrates In Vitro Activity against Members of the Fusarium oxysporum and Fusarium solani Species Complexes

Badali, H., Patterson, H. P., Sanders, C. J., Mermella, B., Gibas, C. F. C., Ibrahim, A. S., Shaw, K. J., & Wiederhold, N. P. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02343-20 · Cited by 43 · see citing works

Update on Outbreak of Fungal Meningitis Among US Residents Who Received Epidural Anesthesia at Two Clinics in Matamoros, Mexico

Smith, D. J., Gold, J. A. W., Chiller, T. M., Bustamante, N. D., Marinissen, M. J., Rodriquez, G. G., González-Cortés, V. B., Duque-Molina, C., Williams, S., Deida, A. A. V., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad570 · Cited by 43 · see citing works

Fosmanogepix for the Treatment of Invasive Mold Diseases Caused by Aspergillus Species and Rare Molds: A Phase 2, Open-Label Study (AEGIS)

Hodges, M. R., Tawadrous, M., Cornely, O. A., Thompson, G. R., Slavin, M. A., Maertens, J. A., Dadwal, S., Rahav, G., Hazel, S., Almas, M., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf185 · Cited by 43 · see citing works

Update on therapeutic approaches for invasive fungal infections in adults

Boutin, C.-A., & Luong, M. (2024) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361231224980 · Cited by 43 · see citing works

Advances in understanding and managing Scedosporium respiratory infections in patients with cystic fibrosis

Bouchara, J., Govic, Y. L., Kabbara, S., Cimon, B., Zouhair, R., Hamzé, M., Papon, N., & Nevez, G. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1705787 · Cited by 33 · see citing works

Antifungal Development and the Urgency of Minimizing the Impact of Fungal Diseases on Public Health

de Oliveira, H. C., Bezerra, B. T., & Rodrigues, M. L. (2022) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.2c00055 · Cited by 41 · see citing works

The antifungal pipeline for invasive fungal diseases: what does the future hold?

Neoh, C. F., Jeong, W., Kong, D. C. M., & Slavin, M. A. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2203383 · Cited by 37 · see citing works

Invasive Scedosporium and Lomentospora prolificans Infections in Australia: A Multicenter Retrospective Cohort Study

Neoh, C. F., Chen, S. C. ‐., Crowe, A., Hamilton, K., Nguyen, Q. A., Marriott, D., Trubiano, J. A., Spelman, T. D., Kong, D. C. M., & Slavin, M. A. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad059 · Cited by 36 · see citing works

Management of Invasive Infections in Diabetes Mellitus: A Comprehensive Review

Khanam, A., Hithamani, G., Jayapala, N., Pradeep, S. R., Barman, S., & Srinivasan, K. (2023) · Biologics · doi:10.3390/biologics3010004 · Cited by 35 · see citing works

<i>In Vitro</i> Activity of Manogepix (APX001A) and Comparators against Contemporary Molds: MEC Comparison and Preliminary Experience with Colorimetric MIC Determination

Jørgensen, K. M., Astvad, K. M. T., & Arendrup, M. C. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00730-20 · Cited by 33 · see citing works

Investigational Agents for the Treatment of Resistant Yeasts and Molds

Seiler, G. T., & Ostrosky-Zeichner, L. (2021) · Current Fungal Infection Reports · doi:10.1007/s12281-021-00419-5 · Cited by 32 · see citing works

The evolution of antifungal therapy: Traditional agents, current challenges and future perspectives

de Souza, C. M., Bezerra, B. T., Mellon, D. A., & de Oliveira, H. C. (2025) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2025.100341 · Cited by 35 · see citing works

Fosmanogepix Therapy of Disseminated Fusarium Infection

Winston, D. J., Young, P. A., Schlamm, H. T., & Schiller, G. J. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad309 · Cited by 28 · see citing works

Fosmanogepix: The Novel Anti-Fungal Agent’s Comprehensive Review of in Vitro, in Vivo, and Current Insights From Advancing Clinical Trials

Almajid, A., Bazroon, A. A., Al-Awami, H., Albarbari, H., Alqahtani, I., Almutairi, R., Alsuwayj, A., Alahmadi, F., Aljawad, J., Alnimer, R., et al. (2024) · Cureus · doi:10.7759/cureus.59210 · Cited by 25 · see citing works

New Ground in Antifungal Discovery and Therapy for Invasive Fungal Infections: Innovations, Challenges, and Future Directions

Niño‐Vega, G. A., Padró-Villegas, L., & López-Romero, E. (2024) · Journal of Fungi · doi:10.3390/jof10120871 · Cited by 30 · see citing works

Target- and prodrug-based design for fungal diseases and cancer-associated fungal infections

Liu, N., Tu, J., Huang, Y., Yang, W., Wang, Q., Li, Z., & Sheng, C. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114819 · Cited by 24 · see citing works

Emerging Diagnostics and Therapeutics for Invasive Fungal Infections

Friedman, D. Z. P., & Schwartz, I. S. (2023) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2023.05.001 · Cited by 23 · see citing works

Antifungal metabolites, their novel sources, and targets to combat drug resistance

Choudhary, M., Kumar, V., Naik, B., Verma, A., Saris, P. E. J., Kumar, V., & Gupta, S. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1061603 · Cited by 23 · see citing works

The Significance of Mono‐ and Dual‐Effective Agents in the Development of New Antifungal Strategies

Zobi, C., & Algül, Ö. (2025) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70045 · Cited by 22 · see citing works

Diagnosis and management of invasive fungal infections due to non-Aspergillus moulds

Morrissey, C. O. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf005 · Cited by 21 · see citing works

Therapeutic Potential of Fosmanogepix (APX001) for Intra-abdominal Candidiasis: from Lesion Penetration to Efficacy in a Mouse Model

Lee, A., Wang, N., Carter, C. L., Zimmerman, M., Dartois, V. A., Shaw, K. J., Perlin, D. S., & Zhao, Y. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02476-20 · Cited by 20 · see citing works

Antifungal resistance, combinations and pipeline: oh my!

Stover, K. R., Hawkins, B. K., Keck, J. M., Barber, K. E., & Cretella, D. A. (2023) · Drugs in Context · doi:10.7573/dic.2023-7-1 · Cited by 19 · see citing works

Advances in anti-fungal therapies

WATERER, G. W. (2021) · Mycopathologia · doi:10.1007/s11046-021-00560-2 · Cited by 20 · see citing works

Antifúngicos de uso sistémico

Quiles‐Melero, I., & García‐Rodríguez, J. (2021) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2021.04.004 · Cited by 18 · see citing works

Current global status of Candida auris an emerging multidrug-resistant fungal pathogen: bibliometric analysis and network visualization

Ettadili, H., & Vural, C. (2024) · Brazilian Journal of Microbiology · doi:10.1007/s42770-023-01239-0 · Cited by 17 · see citing works

Mitochondrial Complex I Core Protein Regulates cAMP Signaling via Phosphodiesterase Pde2 and NAD Homeostasis in Candida albicans

She, X., Zhang, L., Peng, J., Zhang, J., Li, H., Zhang, P., Calderone, R., Liu, W., & Li, D. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.559975 · Cited by 16 · see citing works

American Society of Transplantation and Cellular Therapy Series: #8-Management and Prevention of Non-Aspergillus Molds in Hematopoietic Cell Transplantation Recipients

Douglas, A. P., Lamoth, F., John, T. M., Groll, A. H., Shigle, T. L., Papanicolaou, G. A., Chemaly, R. F., Carpenter, P. A., Dadwal, S., Walsh, T. J., et al. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.01.892 · Cited by 15 · see citing works

How do I manage refractory invasive pulmonary aspergillosis

Vergidis, P., Sendi, P., Alkhateeb, H. B., & Nguyen, M. H. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.01.015 · Cited by 12 · see citing works

Non-Aspergillus Hyaline Molds: A Host-Based Perspective of Emerging Pathogenic Fungi Causing Sinopulmonary Diseases

Jacobs, S. E., & Walsh, T. J. (2023) · Journal of Fungi · doi:10.3390/jof9020212 · Cited by 13 · see citing works

The antifungal pipeline: the need is established. Are there new compounds?

Li, D., She, X., & Calderone, R. (2020) · FEMS Yeast Research · doi:10.1093/femsyr/foaa023 · Cited by 15 · see citing works

Cerebral Aspergillosis: Diagnostic Challenges, Therapeutic Strategies, and Future Research

Chantelot, L., Sitterlé, E., Poirée, S., Jullien, V., Danion, F., & Serris, A. (2025) · CNS Drugs · doi:10.1007/s40263-025-01241-0 · Cited by 11 · see citing works

Meeting the Therapeutic Challenges of Emergent and Rare Invasive Fungal Diseases Through Novel Clinical Trial Designs

Walsh, T. J. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae257 · Cited by 11 · see citing works

Phase 1 drug-drug interaction study to assess the effect of CYP3A4 inhibition and pan-CYP induction on the pharmacokinetics and safety of fosmanogepix in healthy participants

Hodges, M. R., van Marle, S., Kramer, W. G., Ople, E., Tawadrous, M., & Jakate, A. S. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01650-23 · Cited by 10 · see citing works

In vitro activity of novel antifungals, natamycin, and terbinafine against Fusarium

Garbe, E., Ullah, A., Aldejohann, A. M., Kurzai, O., Janevska, S., & Walther, G. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01913-24 · Cited by 10 · see citing works

Development of E1224 by leveraging a strategic partnership for the medicines creation against neglected tropical diseases

Hata, K. (2020) · Parasitology International · doi:10.1016/j.parint.2020.102278 · Cited by 9 · see citing works

Fungal Meningitis in US Patients Who Received Epidural Anesthesia in Matamoros, Mexico

Smith, D. J., Misas, E., Gold, J. A. W., Evert, N., Dang, T., Prot, E., Godwin, S., Rivas, J., Pearson, J., Koenecke, L., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf399 · Cited by 8 · see citing works

In Vitro Activity of APX2041, a New Gwt1 Inhibitor, and In Vivo Efficacy of the Prodrug APX2104 against Aspergillus fumigatus

Shaheen, S. K., Juvvadi, P. R., Allen, J., Shwab, E. K., Cole, D., Asfaw, Y. G., Kapoor, M., Shaw, K. J., & Steinbach, W. J. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00682-21 · Cited by 8 · see citing works

Therapeutic Approaches for Combating Aspergillus Associated Infection

Chhillar, A. K., Punia, A., Choudhary, P., Sharma, N., Dahiya, S., & Gulia, P. (2022) · Current Drug Targets · doi:10.2174/1389450123666220623164548 · Cited by 7 · see citing works

Invasive fungal infections in hematologic diseases: evidence, challenges, and clinical practice

Cho, S., Lee, C. E., Nho, D., & Lee, D. (2025) · Blood Research · doi:10.1007/s44313-025-00113-2 · Cited by 7 · see citing works

Antifungal therapy for the treatment of CNS infections

Aboabdo, M., & Mishkin, A. D. (2024) · Current Fungal Infection Reports · doi:10.1007/s12281-024-00492-6 · Cited by 7 · see citing works

The combination of manogepix and itraconazole is synergistic and inhibits the growth of Madurella mycetomatis in vitro but not in vivo

Konings, M., Eadie, K., Strepis, N., Nyuykonge, B., Fahal, A. H., Verbon, A., & van de Sande, W. W. J. (2023) · Medical Mycology · doi:10.1093/mmy/myad118 · Cited by 7 · see citing works

Future Directions for Clinical Respiratory Fungal Research

Armstrong-James, D. P. H. (2021) · Mycopathologia · doi:10.1007/s11046-021-00579-5 · Cited by 6 · see citing works

Efficacy assessments of SF001, a next-generation polyene antifungal, in a neutropenic mouse model of invasive fusariosis

Gebremariam, T., Gu, Y., Patterson, H. P., Youssef, E. G., Alkhazraji, S., Elsayed, T., Wiederhold, N. P., & Ibrahim, A. S. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01802-24 · Cited by 5 · see citing works

New and emerging drugs for the treatment of invasive fungal infections

Maves, R. C., & Fowler, M. N. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2568547 · Cited by 5 · see citing works

Molecular Targeting and Novel Therapeutic Approaches against Fungal Infections

Kumar, A., Bansal, P., Katiyar, D., Prakash, G. K. S., & Rao, N. G. R. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230302123310 · Cited by 5 · see citing works

Models for Studying Fungal Pathogenesis

Curtis, A., Oladimeji, F., & Kavanagh, K. A. (2025) · Current Clinical Microbiology Reports · doi:10.1007/s40588-025-00249-w · Cited by 4 · see citing works

Challenges in management of invasive fungal infections in stem cell transplant

Walker, J. B., Edwards, S., Hall, N. M., & Pappas, P. G. (2023) · Transplant Infectious Disease · doi:10.1111/tid.14175 · Cited by 4 · see citing works

Successful treatment of a resistant invasive disseminated Fusarium infection in an immunocompetent patient

Frantzeskaki, F. G., Stratopoulos, N., van der Griend, S. E., Renieris, I., Thomas, Κ., & Tsagkaris, I. (2025) · Medical Mycology Case Reports · doi:10.1016/j.mmcr.2025.100750 · Cited by 3 · see citing works

New Perspectives on Antimicrobial Agents: Fosmanogepix

Lamoth, F. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00324-26 · Cited by 3 · see citing works

Scedosporium species and Lomentospora prolificans fungaemia is uniformly fatal in patients with haematological malignancy

Stewart, A. G., Heney, C., Paterson, D. L., Harris, P. N. A., Edwards, F., & Laupland, K. B. (2023) · Internal Medicine Journal · doi:10.1111/imj.16198 · Cited by 3 · see citing works

In vitro manogepix susceptibility testing of South African Emergomyces africanus, Emergomyces pasteurianus , and Blastomyces emzantsi clinical isolates

Nzimande, S., Govender, N. P., & Maphanga, T. G. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01104-23 · Cited by 3 · see citing works

An Insight into the Repurposing of Phytoconstituents obtained from Delhi’s Aravalli Biodiversity Park as Antifungal Agents

Kaur, A., Sharma, K., Sharma, N., & Aggarwal, G. (2024) · Infectious Disorders - Drug Targets · doi:10.2174/0118715265282411240119061441 · Cited by 3 · see citing works

Invasive mould infection in children – advances made or obstacles remaining?

Yeoh, D. K., Butters, C. T., Clark, J. E., Slavin, M. A., McMullan, B. J., Haeusler, G. M., & Blyth, C. C. (2025) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2025.11.023 · Cited by 3 · see citing works

New Antimycotics in the Pipeline – For Ophthalmology Too?

Behrens‐Baumann, W. (2021) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1478-4248 · Cited by 3 · see citing works

Olecranon bursitis caused by Scedosporium apiospermum in a patient treated with CAR-T cells

Falkenburg, W. J. J., Jalink, M., Kersten, M. J., Buil, J. B., & van Dijk, K. (2022) · Medical Mycology Case Reports · doi:10.1016/j.mmcr.2022.10.002 · Cited by 3 · see citing works

Novel agents in the treatment of invasive fungal infections in solid organ transplant recipients

Cabrera, N. L., George, I. A., Rauseo, A. M., Mazi, P. B., & Spec, A. (2022) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000995 · Cited by 3 · see citing works

Multisystem Lomentospora prolificans progression on fosmanogepix despite in vitro activity: a call for expanding clinical research on novel antifungals

Cooper, R. J., Arif, S., Baker, A. W., Wiederhold, N. P., Sarantopoulos, S., Iftikhar, M., Stanly, K., Collis, B. J., Ni, B., Sim, B., et al. (2026) · ASM Case Reports · doi:10.1128/asmcr.00189-25 · Cited by 2 · see citing works

Novel antifungal compounds against Fusarium spp: A systematic review

de León, N. A., Álvarez‐Villalobos, N. A., Gonzalez, G. H., Treviño‐Rangel, R. D. J., & Montoya, A. M. (2026) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2026.503109 · Cited by 2 · see citing works

Novel Inositol Acyltransferase (Gwt1) Inhibitor for Fungal Keratitis Treatment: Evaluation of In Vitro and In Vivo Efficacy and Safety

Gowtham, L., Meghana, Y., Mannangatty, T., Vasavi, S., Nirmal, J., Bagga, B., Garg, P., Mishra, D., & Roy, S. (2026) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.67.4.49 · Cited by 2 · see citing works

Manogepix demonstrates potent in vitro activity against Aspergillus, Coccidioides , Scopulariopsis/Microascus, Rasamsonia , and Purpureocillium species, including strains with in vitro resistance to other antifungals

Wiederhold, N. P., Patterson, H. P., Sanders, C. J., & Cañete-Gibas, C. F. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00476-26 · Cited by 2 · see citing works

Wild-type MIC distributions and epidemiological cut-off values for ibrexafungerp, manogepix, and rezafungin against WHO fungal priority pathogens

Morelo, M. J., Firacative, C., García‐Effrón, G., Gómez, B. L., & Ceballos-Garzón, A. (2026) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2026.107870 · Cited by 1 · see citing works

Aspergillus-Human Interactions: From the Environment to Clinical Significance

Thammahong, A. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.98509

Pneumonia caused by Scedosporium in non-Transplant and non-HIV-infected adults：A case series and review of the literaturePreprint

Wang, A., Yang, P., Gong, Y., Wang, Y., & Chen, N. (2022) · doi:10.22541/au.166204623.34924109/v1

Clinical status of anticandidal therapeutic agents

Kumar, A., & Jha, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18744-5.00004-6

Non-Aspergillus Pulmonary Mold Infections

Muthu, V., & Chakrabarti, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-76524-7_25

Antifungal Agents and Therapeutic Approaches in the Treatment of Invasive Fungal Infections

Choudhary, P., Punia, A., Kumari, S., & Chhillar, A. K. (2025) · Current Bioactive Compounds · doi:10.2174/0115734072368372250203055808

Novel Therapeutic Approaches to Control Fungal Biofilms

Guisso, L. P., Ribeiro, N. P., Carmona, W. R., Roseno, A. C. B., Pessan, J. P., & Monteiro, D. R. (2025) · Springer series on biofilms · doi:10.1007/978-3-031-93315-8_11

Non-Aspergillus molds

Eichenberger, E. M., Mendoza, M. A., & Baddley, J. W. (2025) · JHLT Open · doi:10.1016/j.jhlto.2025.100382

Management of fusariosis in transplant patients

Gandolpho, L. S., & Nucci, M. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2624618

Novel antifungal compounds against Fusarium spp: A systematic review

de León, N. A., Álvarez‐Villalobos, N. A., González, G. M., Treviño‐Rangel, R. D. J., & Montoya, A. M. (2026) · Enfermedades infecciosas y microbiologia clinica (English ed ) · doi:10.1016/j.eimce.2026.503109

Integrin ß4 is a receptor for emerging fungal pathogens from the genera Lomentospora and Scedosporium

Kavaliauskas, P., Risteen, R. G., Alkhazraji, S., Shirtliff, B., Walsh, T. J., Ibrahim, A. S., & Bruno, V. M. (2026) · PLoS Pathogens · doi:10.1371/journal.ppat.1014107

Invasive Fusariosis in Immunocompromised Cancer Patients

Andreadakis, J. D., Kornblum, D. S., Quilitz, R. E., Greene, J., Lamphier, I., & Velez, A. P. (2026) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0000000000001602

Invasive mold infections in the pediatric setting: current status and new developments

Warris, A., Rojo, P., Groll, A. H., & Arrieta, A. C. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2672541

Emerging antifungal agents in human medicine: Mechanisms, clinical progress, and future perspectives

Al‐Zoubi, R. M., Farhan, A., Hanbali, B., Al-Zoubi, S. R., Al-Zoubi, Y. R., Shkoor, M., Alkharraz, L. M., Agouni, A., & Al-Jabiry, A. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119194

Clinical Efficacy and Safety of Fosmanogepix in Patients with Invasive and Refractory Fungal Infections: A Systematic Review

Bratosin, F., Bogdan, I. G., & Pescariu, S. A. (2026) · Journal of Fungi · doi:10.3390/jof12100733

Highlighting gaps in paediatric antifungal drugs: a qualitative synthesis of current data from the International Pediatric Association AMR Working Group

Dharmapalan, D., Singh, M., El-Shabrawi, M. H. F., Murray, T. S., Sadoh, A. E., Simental, L. P. S., Ibanes-Gutiérrez, C., Efstathiou, E., Fathy, H. M., Rath, B. A., et al. (2026) · Frontiers in Tropical Diseases · doi:10.3389/fitd.2026.1970689

Fosmanogepix (APX001) Is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to Rhizopus arrhizus

Gebremariam, T., Alkhazraji, S., Alqarihi, A., Wiederhold, N. P., Shaw, K. J., Patterson, T. F., Filler, S. G., & Ibrahim, A. S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00178-20 · Cited by 88 · see citing works

The Combination Treatment of Fosmanogepix and Liposomal Amphotericin B Is Superior to Monotherapy in Treating Experimental Invasive Mold Infections

Gebremariam, T., Gu, Y., Alkhazraji, S., Youssef, E. G., Shaw, K. J., & Ibrahim, A. S. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00380-22 · Cited by 61 · see citing works

Fosmanogepix Therapy of Disseminated Fusarium Infection

Winston, D. J., Young, P. A., Schlamm, H. T., & Schiller, G. J. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad309 · Cited by 28 · see citing works

Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections

Shaw, K. J., & Ibrahim, A. S. (2020) · Journal of Fungi · doi:10.3390/jof6040239 · Cited by 229 · see citing works

726. APX001 (Fosmanogepix) Is Effective in an Immunosuppressed Mouse Model of Rhizopus oryzae Infection

Gebremariam, T., Alkhazraji, S., Gu, Y., Alqarihi, A., Mamouei, Z., Shaw, K. J., & Ibrahim, A. S. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz360.794 · Cited by 3 · see citing works